Previous studies have shown that systemic, but not unilateral intra-prefrontal cortex administration of non-competitive NMDA antagonists, increased prefrontal activity, the cortical efflux of serotonin, and induced stereotypies. In this work we used in-vivo microdialysis and immunohistochemistry to test the hypothesis as to whether MK-801 and ketamine need to act on both prefrontal cortices to reproduce these neurochemical and behavioural changes. Dialysis probes were implanted in the medial prefrontal cortex, and extracellular serotonin as well as behavioural stereotypies was measured after systemic administration of MK-801 and ketamine (1 mg/kg and 25 mg/kg, respectively), and unilateral and bilateral perfusion of both drugs (300 mM and 3 mM, respectively). Additionally, the prefrontal (glutamatergic) level of activity was measured using c-Fos immunohistochemistry. Systemic and bilateral (but not unilateral) prefrontal administration of MK-801 and ketamine increased serotonin efflux whereas only systemic administration of both drugs produced hyperlocomotion and stereotypies. The unilateral perfusion of 1 mM tetrodotoxin in the medial prefrontal cortex reduced increases of serotonin in both hemispheres, the expression of c-Fos in the contralateral side, and stereotypy scores after systemic NMDA antagonists. Our results support the hypothesis that a bilateral impairment of cortical inhibition in the medial prefrontal cortex is needed for non-competitive NMDA antagonists to induce the state of pyramidal cell hyperactivity and concurrent efflux of serotonin. Furthermore, hyperlocomotion and stereotypies produced by MK-801 and ketamine do not appear to result from changes in the activity of prefrontal cortex although this structure exerts some control over these behaviours.
Introduction
The hypothesis of N-methyl-D-aspartate (NMDA) receptor hypofunction in schizophrenia stems from the observation that NMDA antagonists, such as phencyclidine (PCP) and ketamine, induce psychotic, negative and cognitive symptoms, that resemble those present in schizophrenia (Javitt & Zukin, 1991 ; Krystal et al. 1994) . Furthermore, several functions that are impaired in schizophrenia (e.g. working memory) are dependent on the integrity of the prefrontal cortex (PFC) (Goldman-Rakic, 1994) . In rats, systemic administration of NMDA antagonists induces hyperlocomotion and stereotypies , behaviours that are commonly associated with positive symptoms of schizophrenia (Lipska & Weinberger, 2003 ; Sams-Dodd, 1997) , and are thought to result from elevated dopaminergic and serotonergic tones (Giros et al. 1996 ; Jentsch et al. 1998) . Accordingly, NMDA receptor blockade increases glutamate and serotonin (5-HT) release in the medial prefrontal cortex (mPFC) of rats (Adams & Moghaddam, 2001 ; Ló pez-Gil et al. 2007 ). These effects occur in parallel with an enhanced prefrontal activity measured as increased firing rate of pyramidal neurons (Jackson et al. 2004 ; Kargieman et al. 2007 ; Suzuki et al. 2002) and expression of c-fos (Kargieman et al. 2007 ; Väisänen et al. 2004 ; Zuo et al. 2009) .
A highly active serotonergic transmission has been implicated in schizophrenia (Meltzer, 1989) and in the hyperlocomotion induced by the ablation of the NR2A subunit of NMDA receptors (Miyamoto et al. 2001) . On the other hand, locomotion and stereotypy induced by 3,4-methylenedioxymethamphetamine (MDMA) is strongly correlated with prefrontal release of 5-HT (Baumann et al. 2008) . However, the precise role of cortical 5-HT on similar effects produced by NMDA antagonists remains to be determined. In a previous work we put forward the idea that an excessive serotonergic efflux in the mPFC can be potentially indicative of negative/cognitive symptomatology of schizophrenia, which is better treated with atypical antipsychotic drugs (Ló pez-Gil et al. 2007) . Furthermore, 5-HT efflux in the mPFC is dependent of the in-vivo excitatory (glutamatergic) transmission in this structure. This is based on two main observations : (1) the stimulation of mPFC output enhances 5-HT efflux in the dorsal raphe nucleus (DR) (Amargó s- Bosch et al. 2003 ; Celada et al. 2001) , which is suggestive of 5-HT cell activation in this structure (Tao & Auerbach, 2000) that would lead to increased 5-HT efflux in the mPFC ; and (2) the increased 5-HT efflux elicited by MK-801 is strongly dependent on the stimulation of a-amino-3-hydroxy-5-methyl-4-isoxazole-4-propionic acid (AMPA) receptors in the mPFC, inasmuch as intra-mPFC perfusion of NBQX (an AMPA receptor antagonist) prevented an increase in 5-HT (and glutamate) levels after systemic MK-801 administration (Ló pez-Gil et al. 2007) . In previous studies using extracellular recordings and microdialysis, unilateral intra-mPFC perfusion of noncompetitive NMDA antagonists failed to replicate the effects of their systemic administration (Aghajanian & Marek, 2000 ; Ló pez-Gil et al. 2007 ; Lorrain et al. 2003 ; Suzuki et al. 2002) , which would suggest an extracortical site(s) of action. In contrast, recent data have suggested that these agents preferentially inhibited prefrontal GABAergic interneurons, thus creating a disinhibited state of pyramidal activity, which is associated with excessive neuronal activity (Homayoun & Moghaddam, 2007) and increased efflux of glutamate and 5-HT within mPFC (Adams & Moghaddam, 2001 ; Ló pez-Gil et al. 2007) . To reconcile such contradictory data, the present work was aimed at examining whether non-competitive NMDA antagonists would need to block NMDA receptors located on GABAergic neurons of mPFC to produce the changes in prefrontal serotonergic transmission (5-HT efflux), pyramidal activity (c-Fos expression in vesicular glutamate transporter-1 (vGluT1)-containing cells) and stereotypies observed after systemic administration. To this end, a microdialysis probe was implanted in each mPFC and extracellular 5-HT and stereotypies were examined after systemic, unilateral and bilateral intra-mPFC administration of MK-801.
Materials and methods

Animals and treatments
Male Wistar rats (Charles River Laboratories, Spain) weighing 250-280 g were used. Food and water were available ad libitum. All experimental procedures followed European Union regulations (Official Journal of the European Communities L358/1, 18 December 1986), and were approved by the Institutional Animal Care and Use Committees. Dizocilpine maleate (MK-801, Sigma-Aldrich, Spain) and ketamine hydrochloride (Tocris Bioscience, UK) were dissolved in saline for intraperitoneal (i.p.) or subcutaneous (s.c.) administration, respectively, or in artificial cerebrospinal fluid (aCSF) for intra-mPFC perfusion. Tetrodotoxin (TTX, Sigma-Aldrich) was dissolved in aCSF. Doses and perfused concentrations of MK-801 and ketamine were selected from previous studies (Ló pez-Gil et al. 2007 ; Moghaddam et al. 1997) , taking into consideration their different affinity for the NMDA channel site (Murray et al. 2000) .
Microdialysis procedures
Concentric dialysis probes with a 4-mm membrane were implanted bilaterally under sodium pentobarbital anaesthesia (60 mg/kg i.p.) in the mPFC (AP+3.2 mm, L¡0.6 mm, DVx6.0 mm from bregma) according to Paxinos & Watson (1986) . Microdialysis experiments were conducted 20-24 h after surgery in freely moving rats by continuously perfusing probes with aCSF (125 mM NaCl, 2.5 mM KCl, 1.26 mM CaCl 2 , 1.18 mM MgCl 2 , 1 mM citalopram) at a rate of 1.5 ml/min. The addition of an uptake inhibitor to the perfusion fluid was used to decrease clearance from the extracellular space and magnify the release component of extracellular 5-HT (Adell et al. 2002) . This did not interfere with the local or systemic actions of the drugs used in the present experiments (Ló pezGil et al. 2007) . Dialysate samples of 30 ml were collected every 20 min, and 5-HT was determined by HPLC as described previously (Ló pez-Gil et al. 2007) . Briefly, the HPLC system consisted of a Waters 717plus autosampler (Waters Cromatografia, Spain), a Hewlett-Packard series 1050 pump (Agilent Technologies, Spain), an octadecyl silica (ODS) column (7.5 cmr0.46 cm ; Beckman, USA), and an amperometric detector Hewlett-Packard 1049 (Agilent Technologies) set at an oxidation potential of 0.6 V. The mobile phase consisted of 0.15 M NaH 2 PO 4 , 1.8 mM octyl sodium sulfate, 0.2 mM EDTA (pH 2.8, adjusted with phosphoric acid), and 30 % methanol and was pumped at 0.7 ml/min. At the completion of dialysis experiments, rats were given an overdose of sodium pentobarbital and a Fast Green solution was perfused through the dialysis probes to stain the surrounding tissue.
c-Fos and vGluT1 immunostaining
In order to mimic microdialysis setting, a group of rats were implanted unilaterally with one probe, and systemic MK-801 was administered i.p. 20-24 h later. c-Fos expression is considered to be a marker of neuronal activity (Dragunow & Faull, 1989) and was measured in the contralateral side to avoid the implantation site in the ipsilateral side. Immunohistochemistry protocol was as described previously (Zuo et al. 2009 ). Briefly, 2 h after administration of MK-801 (1 mg/kg), rats were deeply anaesthetized with sodium pentobarbital (60 mg/kg) and then perfused transcardially with cold 0.9 % NaCl followed by 10 % buffered formalin (Sigma-Aldrich). Each brain was removed immediately, post-fixed in the same fixative for 24 h at 4 xC, and then cut on a vibratome in the coronal plane at 30 mm. Three consecutive sections of the mPFC and DR for each rat were collected free floating. Sections were incubated for 25 min at room temperature (RT) in 3 % H 2 O 2 to inactivate endogenous peroxidase. Thereafter, sections were washed twice in 0.01 M PBS containing 0.2 % Triton X-100. After blocking with 5 % BSA for 1 h at RT, sections were incubated overnight at 4 xC with rabbit polyclonal antiserum raised against c-Fos (sc-50, Santa Cruz Biotechnology, USA) diluted 1 : 500 in PBS containing 0.2 % Triton X-100, 0.2 % gelatin and 5 % BSA. Following incubation in the primary antibody, sections were washed three times in PBS containing 0.2 % Triton X-100 and incubated with biotinylated goat anti-rabbit immunoglobulin G (IgG) antiserum (1 : 200, Vector Laboratories, USA), for 1 h at RT. Sections were then washed with PBS containing 0.2 % Triton X-100, incubated for 1 h with avidin-biotin peroxidase complex (1 : 1000 ; Vectastain ABC kit, Vector Laboratories), washed in 0.01 M PBS, and finally revealed with diaminobenzidine for 10-15 min. Sections were then slide-mounted onto gelatin-coated slides. The number of c-Fos-positive cells in mPFC and DR were measured in triplicate. The procedure also included negative controls with omission of the primary antibody, which did not show any immunoreaction (data not shown). c-Fos-positive nuclei were counted relative to a threshold based on staining density, which was established by visual observation blinded to treatment. Although the threshold is a subjective measure, the stereological cell counting provided a sensible improvement of the method accuracy.
In order to examine whether mPFC cells immunoreactive for c-Fos after MK-801 administration were pyramidal neurons, a double immunohistochemistry procedure was performed combining c-Fos and vGluT1 immunostaining, the latter being a specific marker of glutamatergic (pyramidal) neurons (Fremeau et al. 2001 ; Omelchenko & Sesack, 2007) . Briefly, after a first immunostaining with c-Fos as described, a second procedure was carried out under the same conditions, but using guinea-pig polyclonal antiserum raised against vGluT1 (Millipore, USA) diluted 1 : 2000, a biotinylated goat anti-guinea-pig IgG antiserum (1 : 200, Millipore), and vector VIP (Vector Laboratories) as chromogen. As described previously (Fremeau et al. 2001) , vGluT1 is distributed peripherally in cortical pyramidal neurons, just underneath the plasma membrane, thus leaving a clear zone that corresponds to the cytoplasm (Fig. 5 b) .
Brain sections were examined in an Olympus BX51 Stereo Microscope (Japan). Stereological cell counting was performed using Visiopharm Integrator System software for stereological analysis (Visiopharm A/S, Denmark).
Behavioural measures
Gross behavioural scores were assessed by direct observation of rats undergoing in-vivo microdialysis and were based on a method described previously (Jackson et al. 2004) . Stereotypies were rated during the last 5 min of each 20-min sample. Animals received a score of 0 (absence), 1 (presence) or 2 (intense ; >50 % of the 5-min block) for each of the following motor stereotypies commonly associated with NMDA antagonism : reciprocal forepaw treading, side-to-side head weaving, and hyperlocomotion (turning). Total scores for each rat were calculated by summing the individual values of each behaviour during each 5-min period.
Statistics
Microdialysate 5-HT (mean¡S.E.M.) was calculated as fmol/30 ml, and is shown in the figures as percentages of basal values, averaged from four fractions collected before treatment. Changes in dialysate 5-HT were analysed by two-way, repeated-measures analysis of variance (ANOVA) with time and treatment as factors, followed by Newman-Keuls (NK) multiple comparison test. The individual stereotypy scores were averaged within each treatment and analysed by oneway ANOVA followed by NK test. Differences in the number of c-Fos immunostained cells among the different treatment groups in mPFC and DR were also tested by one-way ANOVA followed by NK test. Statistical calculations were made using Statistica software (StatSoft Inc., USA). Differences were considered significant when p<0.05.
Results
Effects of MK-801 and ketamine on cortical 5-HT Two-way ANOVA showed that, with respect to saline-injected group, the administration of MK-801 (1 mg/kg) enhanced the extracellular concentration of 5-HT to the same extent in both mPFCs (Fig. 1a) as demonstrated by the significant effect of treatment (F 3,34 =13.7, p<0.00001), time (F 15,510 =13.9, p<0.00001), and treatmentrtime interaction (F 45,510 =4.2, p< 0.00001). Figure 1 b depicts the effects of uni-or bilateral infusion of MK-801 on the efflux of 5-HT in the mPFC. Two-way ANOVA showed that the unilateral perfusion of MK-801 (300 mM) had no effect, but bilateral perfusion of MK-801 increased the extracellular concentration of 5-HT to the same extent in both mPFCs as demonstrated by the significant effect of treatment (F 3,30 =10.8, p<0.0001), time (F 15,450 =11.0, p<0.00001), and treatmentrtime interaction (F 45,450 = 3.4, p<0.00001). In a similar manner, two-way ANOVA showed that, with respect to the salineinjected group, administration of ketamine (25 mg/kg) enhanced the extracellular concentration of 5-HT to the same extent in both mPFCs (Fig. 2 a) as demonstrated by the significant effect of treatment (F 3,18 =6.4, p<0.01), time (F 15,270 =10.5, p<0.00001), and treatmentrtime interaction (F 45,270 =4.1, p<0.00001). Moreover, two-way ANOVA showed that the unilateral perfusion of ketamine (3 mM) had no effect, but bilateral perfusion of ketamine increased the extracellular concentration of 5-HT to the same extent in both mPFCs (Fig. 2 b) as demonstrated by the significant effect of treatment (F 3,22 =4.1, p<0.02), time (F 15,330 =3.2, p<0.0001), and treatmentrtime interaction (F 45,330 =1.5, p<0.02). There was no difference in the level of 5-HT between both hemispheres after bilateral application of MK-801 and ketamine.
The effects of the perfusion of TTX alone and in combination with MK-801 or ketamine are depicted in Fig. 3 . The perfusion of 1 mM TTX unilaterally in the mPFC abolished locally the basal concentration of 5-HT without altering its concentration in the contralateral mPFC (Fig. 3a) , as shown by the significant effect of treatment (F 3,26 =24.9, p<0.000001), time (F 15,390 =11.2, p<0.000001), and treatmentrtime interaction (F 45,390 =8.2, p<0.000001). Further, the unilateral perfusion of 1 mM TTX in the mPFC not only abolished the local increase in 5-HT elicited by the systemic administration of MK-801, but also reduced significantly the effect of MK-801 in the contralateral part (Fig. 3b) , as demonstrated by the significant effect of treatment (F 5,56 =51.1, p<0.000001), time (F 15,840 =16.7, p<0.000001), and treatmentrtime interaction (F 75,840 = 17.2, p<0.000001). Similar actions of TTX were observed in rats given ketamine systemically (Fig. 3 c) .
Thus, the unilateral perfusion of 1 mM TTX in the mPFC abolished the local increase in 5-HT elicited by the systemic administration of ketamine in the ipsilateral and contralateral hemispheres, as shown by the significant effect of treatment (F 5,28 =22.8, p<0.000001), time (F 15,420 =8.3, p<0.000001), and treatmentrtime interaction (F 75,420 =7.5, p<0.000001).
Effects of MK-801 on c-Fos and vGluT1 immunohistochemistry
The activation of cortical and raphe cells, measured by c-Fos immunohistochemistry, was examined after systemic administration of only MK-801 (1 mg/kg) because this agent displays higher affinity and selectivity for the NMDA channel site (Murray et al. 2000) . One-way ANOVA showed a significant effect of group on the number c-Fos-positive cells in the mPFC (F 2,11 =105.1, p<0.0001 ; Fig 
Effects of MK-801 and ketamine on behavioural scores
One-way ANOVA showed a significant effect of group on the stereotypy scores induced by MK-801 (F 5,71 = 153.6, p<0.0001 ; Fig. 6 a) and ketamine (F 5,43 =155.3, p<0.0001 ; Fig. 6 b) . The systemic administration of both NMDA antagonists significantly increased the behavioural scores of stereotypical behaviour (p<0.001, NK test for MK-801 ; p<0.001, NK test for ketamine). Neither unilateral nor bilateral application of MK-801 or ketamine produced the emergence of such behaviours. However, unilateral perfusion of TTX in the right mPFC significantly reduced the behavioural scores obtained after systemic administration of MK-801 (p<0.001, NK test) and ketamine (p<0.001, NK test).
Discussion
Whether NMDA antagonists act preferentially within the PFC or by influencing the activity of cortical afferents is not clear. Some studies have shown that intrathalamic (Sharp et al. 2001) or hippocampal (Jodo et al. 2005) injection of NMDA antagonists mimic the effects of systemic administration better than intra-mPFC application, thus suggesting that, at least some of the effects, are caused by influencing the activity of thalamic or hippocampal projections. For instance, an activation of thalamocortical pathways may be partly responsible for these effects (Santana et al. 2011) . Systemic administration of non-competitive NMDA antagonists also induced behavioural activation and enhanced the efflux of glutamate and 5-HT in the mPFC (Adams & Moghaddam, 2001 ; Ló pez-Gil et al. 2007 ; Lorrain et al. 2003 ; Moghaddam et al. 1997) , effects that were not observed following the unilateral intra-mPFC perfusion of such drugs (Ló pez-Gil et al.
; Lorrain et al. 2003).
Here we observed that systemic MK-801 evoked a sustained increase in 5-HT that lasted more than 4 h whereas the effect of ketamine returned to baseline level within 3 h. This pharmacokinetic difference is probably due to the shorter half-life of ketamine. The present results support the view that the PFC is a pivotal site of action of NMDA antagonists. Indeed, bilateral (but not unilateral) perfusion of MK-801 in the mPFC elicited an increase of cortical 5-HT efflux, which, in its maximal effect, was comparable to that seen after systemic administration. The slower time-course of increase in 5-HT with intra-mPFC application compared to systemic administration is probably due to smaller extracellular concentration of the drug confined to a limited volume of tissue. The unilateral perfusion of TTX in mPFC diminished 5-HT efflux induced by systemic MK-801 not only in the ipsilateral mPFC, but also to great extent in the contralateral mPFC, which confirms that an important locus for these effects is in the mPFC. This is further emphasized by the observation that ketamine experiments replicated the MK-801 effects fairly well. Overall, this suggests that the effects of systemic non-competitive NMDA antagonists on prefrontal 5-HT, and probably the overall state of mPFC hyperexcitability that underlies it, require bilateral disruptions of the mPFC. However, the question that remains, i.e. whether the bilateral perfusion of MK-801 and ketamine produces a larger stimulation of 5-HT cells in the DR or prefrontal interconnectivity, is indeed crucial for this purpose. To test the mechanism underlying our results, we applied TTX to unilateral mPFC in the setting of systemic NMDA receptor blockade, and measured the number of c-Fos cells in the contralateral mPFC and the DR. The TTX experiments here describe a marked dissociation for the effects on c-Fos in the contralateral mPFC vs. the DR following systemic MK-801 administration. Furthermore, while the local infusion of TTX almost completely attenuated the MK-801-induced increase in 5-HT in the contralateral mPFC, the MK-induced increase in the number of c-Fos cells was attenuated by only about 25 %. Unilateral perfusion of Control mPFC mPFC ** ** ** ** * TTX also reduced the activity of pyramidal cells (measured as the number of cells positive for c-Fos and vGluT1) in the contralateral mPFC. However, TTX application did not alter the number of c-Fos-positive cells in the DR after systemic MK-801, which disfavors a greater activation of 5-HT neurons and supports the idea that bilateral disruption of the mPFC is indeed required to mimic the effects of systemic non-competitive NMDA antagonists. Although this phenomenon appears clear cut, the underlying cellular mechanisms remain to be determined. In any event, our results can be explained by a preferential activation of cortico-raphe projections rather than by a direct action of these compounds on the DR. It must be noted, however, that these effects seem to apply only to non-competitive NMDA antagonists inasmuch as competitive antagonists increase cortical 5-HT following unilateral exposure (Calcagno et al. 2006) . However, it is also possible that, in addition to the competitive vs. non-competitive nature, some compounds differ also in pharmaco-distribution and pharmaco-dynamics as well as acting at other transmitter receptors. Previous work has lent support to the view that non-competitive NMDA receptor antagonists reduce selectively GABAergic inhibition of pyramidal cells, thus leading to a disinhibited state of pyramidal activity (Krystal et al. 2003 ; Moghaddam et al. 1997 ; Olney & Farber, 1995) , which is associated with excessive neuronal activity and efflux of glutamate and 5-HT within the mPFC (Adams & Moghaddam, 2001 ; Ló pez-Gil et al. 2007) . The increase of 5-HT concentration most likely results from the elevation of the excitatory output of a subpopulation of pyramidal neurons in layer V of mPFC that project heavily to the DR (Gabbott et al. 2005) and tightly control the activity of 5-HT cells (Celada et al. 2001 ; Hajó s et al. 1998) . Recent data (Homayoun & Moghaddam, 2007) and the present study further suggest that these inhibitory neurons are located within the mPFC. In line with this assumption, it has been shown that PCP and MK-801 reduce the extracellular concentration of GABA in the mPFC (Yonezawa et al. 1998 ). Here we show that the percentage of vGluT1-negative cells that express c-Fos (18 %) is coincident with the proportion of GABAergic cells in cortical structures and thus it is tempting to speculate that, in the conditions of the present study, these presumed GABAergic cells are also activated by MK-801, in line with what has been observed previously after PCP (Santana et al. 2011) . This would be in accord with tract-tracing studies showing that callosal terminals primarily target pyramidal neurons, but a proportion of them also synapse onto GABAergic interneurons (Carr & Sesack, 1998) .
In contrast to the changes in serotonergic transmission, the mPFC itself is not sufficient to drive the locomotor activation induced by NMDA antagonists because the bilateral perfusion of MK-801 and ketamine did not evoke hyperlocomotion and stereotypies, which is in accord with results showing that MK-801-induced stereotypies are mostly independent of mPFC integrity (Scorza et al. 2008) . NMDA receptor antagonists could also be acting within the mPFC and the orbital cortex, thus activating corticostriatal non-vGluT1 pathways (West & Grace, 2002) and inducing an increase in horizontal locomotion. However, previous findings indicate that these behaviours are somewhat accounted for by a direct action of NMDA antagonists on caudate putamen and nucleus accumbens (Burns et al. 1994 ; De Leonibus et al. 2001 ; Kelley et al. 1986 ; McCullough & Salamone, 1992 ; Mogenson et al. 1980) . It is of note that these effects were observed only when NMDA antagonists were administered bilaterally, thus indicating that, in line with our observations, both hemispheres must be affected for the emergence of these behaviours. In this regard, it is also important to mention that hippocampal-accumbal projections may play a role in mediating the increase in locomotor activity elicited by NMDA receptor antagonists (Jodo et al. 2005) . In the present work, however, unilateral perfusion of TTX in the mPFC reduced stereotypy scores induced by systemic MK-801 and ketamine. Interestingly, these changes occur in parallel with those of pyramidal activity (measured as c-Fos production in vGluT1-positive cells) and 5-HT efflux, which is in line with the finding that the stereotypies elicited by certain doses of MK-801 correlate with pyramidal cell firing in the PFC (Jackson et al. 2004) . Also in line with these effects, Takahata & Moghaddam (2003) found that application of an AMPA receptor antagonist in the mPFC abolished locomotor activity and stereotypy elicited by systemic PCP. Therefore, although the hyperlocomotion and stereotypies observed do not seem to originate in the mPFC, this brain region appears to mediate the ability to reduce the emergence of these behaviours. Bilateral prefrontal projections to dorsal and ventral striatum (Gabbott et al. 2005 ; Sesack et al. 1989) are probably responsible for the behavioural contributions of these interconnected structures. In summary, the results of this study support the view that an abnormal communication between both prefrontal cortices would lead to a state of cortical hyperactivity measured as increased 5-HT efflux and c-Fos expression. However, a clear dissociation has been found between these neurohistological changes in PFC and behavioural stereotypies, which did not appear to be generated as a consequence of mPFC function. Therefore, it would appear that the circuitry governing the increases in extracellular 5-HT, c-Fos and stereotypical behaviour are different when examining effects of systemic vs. uni-or bilateral non-competitive NMDA antagonists together with the influence of unilateral TTX. Blockade of noncompetitive NMDA receptor antagonist-induced increases in locomotor activity is a key finding used throughout the pharmaceutical industry in supporting novel antipsychotic drug development. Thus, a better knowledge of the somewhat separate but partially overlapping circuits involved in mediating the various behavioural and neurochemical effects of NMDA receptor antagonists would be likely to increase the predictive utility of this model. In this regard, putative antipsychotic drugs should be able to block the multiple effects of this class of psychotomimetic drugs.
